Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.

Paraiso KH, Das Thakur M, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, Pasquale EB, Villagra A, Rao UN, Kirkwood JM, Meier F, Sloot S, Gibney GT, Stuart D, Tawbi H, Smalley KS.

Cancer Discov. 2015 Mar;5(3):264-73. doi: 10.1158/2159-8290.CD-14-0293. Epub 2014 Dec 26.

2.

Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models.

Smyth T, Paraiso KHT, Hearn K, Rodriguez-Lopez AM, Munck JM, Haarberg HE, Sondak VK, Thompson NT, Azab M, Lyons JF, Smalley KSM, Wallis NG.

Mol Cancer Ther. 2014 Dec;13(12):2793-2804. doi: 10.1158/1535-7163.MCT-14-0452. Epub 2014 Oct 27.

3.

Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.

Rebecca VW, Alicea GM, Paraiso KH, Lawrence H, Gibney GT, Smalley KS.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1154-8. doi: 10.1111/pcmr.12303. Epub 2014 Sep 1.

4.

Evaluating melanoma drug response and therapeutic escape with quantitative proteomics.

Rebecca VW, Wood E, Fedorenko IV, Paraiso KH, Haarberg HE, Chen Y, Xiang Y, Sarnaik A, Gibney GT, Sondak VK, Koomen JM, Smalley KS.

Mol Cell Proteomics. 2014 Jul;13(7):1844-54. doi: 10.1074/mcp.M113.037424. Epub 2014 Apr 23.

5.

Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.

Haarberg HE, Paraiso KH, Wood E, Rebecca VW, Sondak VK, Koomen JM, Smalley KS.

Mol Cancer Ther. 2013 Jun;12(6):901-12. doi: 10.1158/1535-7163.MCT-12-1003. Epub 2013 Mar 28.

6.

Fibroblast-mediated drug resistance in cancer.

Paraiso KH, Smalley KS.

Biochem Pharmacol. 2013 Apr 15;85(8):1033-41. doi: 10.1016/j.bcp.2013.01.018. Epub 2013 Jan 29. Review.

PMID:
23376122
7.

Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells.

Beck D, Niessner H, Smalley KS, Flaherty K, Paraiso KH, Busch C, Sinnberg T, Vasseur S, Iovanna JL, Drießen S, Stork B, Wesselborg S, Schaller M, Biedermann T, Bauer J, Lasithiotakis K, Weide B, Eberle J, Schittek B, Schadendorf D, Garbe C, Kulms D, Meier F.

Sci Signal. 2013 Jan 29;6(260):ra7. doi: 10.1126/scisignal.2003057.

8.

GSK3β inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation.

John JK, Paraiso KH, Rebecca VW, Cantini LP, Abel EV, Pagano N, Meggers E, Mathew R, Krepler C, Izumi V, Fang B, Koomen JM, Messina JL, Herlyn M, Smalley KS.

J Invest Dermatol. 2012 Dec;132(12):2818-27. doi: 10.1038/jid.2012.237. Epub 2012 Jul 19.

9.

Making sense of MEK1 mutations in intrinsic and acquired BRAF inhibitor resistance.

Paraiso KH, Smalley KS.

Cancer Discov. 2012 May;2(5):390-2. doi: 10.1158/2159-8290.CD-12-0128.

10.

Lineage extrinsic and intrinsic control of immunoregulatory cell numbers by SHIP.

Collazo MM, Paraiso KH, Park MY, Hazen AL, Kerr WG.

Eur J Immunol. 2012 Jul;42(7):1785-95. doi: 10.1002/eji.201142092.

11.

Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies.

Kudchadkar R, Paraiso KH, Smalley KS.

Cancer J. 2012 Mar-Apr;18(2):124-31. doi: 10.1097/PPO.0b013e31824b436e. Review.

12.

The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.

Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y, Ribas A, Lo RS, Weber JS, Sondak VK, John JK, Sarnaik AA, Koomen JM, Smalley KS.

Clin Cancer Res. 2012 May 1;18(9):2502-14. doi: 10.1158/1078-0432.CCR-11-2612. Epub 2012 Feb 20.

13.

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.

Fedorenko IV, Paraiso KH, Smalley KS.

Biochem Pharmacol. 2011 Aug 1;82(3):201-9. doi: 10.1016/j.bcp.2011.05.015. Epub 2011 May 25. Review.

14.

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.

Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, Ribas A, Palma MD, Nathanson KL, Koomen JM, Messina JL, Smalley KS.

Cancer Res. 2011 Apr 1;71(7):2750-60. doi: 10.1158/0008-5472.CAN-10-2954. Epub 2011 Feb 11.

15.

Measurement of constitutive MAPK and PI3K/AKT signaling activity in human cancer cell lines.

Paraiso KH, Van Der Kooi K, Messina JL, Smalley KS.

Methods Enzymol. 2010;484:549-67. doi: 10.1016/B978-0-12-381298-8.00027-7.

16.

Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis.

Nogueira C, Kim KH, Sung H, Paraiso KH, Dannenberg JH, Bosenberg M, Chin L, Kim M.

Oncogene. 2010 Nov 25;29(47):6222-32. doi: 10.1038/onc.2010.349. Epub 2010 Aug 16.

17.

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

Paraiso KH, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK, Messina JL, Flaherty KT, Smalley KS.

Br J Cancer. 2010 Jun 8;102(12):1724-30. doi: 10.1038/sj.bjc.6605714.

18.

SHIP influences signals from CD48 and MHC class I ligands that regulate NK cell homeostasis, effector function, and repertoire formation.

Fortenbery NR, Paraiso KH, Taniguchi M, Brooks C, Ibrahim L, Kerr WG.

J Immunol. 2010 May 1;184(9):5065-74. doi: 10.4049/jimmunol.0901862. Epub 2010 Apr 2.

19.

SHIP1 inhibition increases immunoregulatory capacity and triggers apoptosis of hematopoietic cancer cells.

Brooks R, Fuhler GM, Iyer S, Smith MJ, Park MY, Paraiso KH, Engelman RW, Kerr WG.

J Immunol. 2010 Apr 1;184(7):3582-9. doi: 10.4049/jimmunol.0902844. Epub 2010 Mar 3.

20.

SHIP limits immunoregulatory capacity in the T-cell compartment.

Collazo MM, Wood D, Paraiso KH, Lund E, Engelman RW, Le CT, Stauch D, Kotsch K, Kerr WG.

Blood. 2009 Mar 26;113(13):2934-44. doi: 10.1182/blood-2008-09-181164. Epub 2009 Jan 9.

21.
22.

Induced SHIP deficiency expands myeloid regulatory cells and abrogates graft-versus-host disease.

Paraiso KH, Ghansah T, Costello A, Engelman RW, Kerr WG.

J Immunol. 2007 Mar 1;178(5):2893-900.

23.

Cutting edge: dominance by an MHC-independent inhibitory receptor compromises NK killing of complex targets.

Wahle JA, Paraiso KH, Costello AL, Goll EL, Sentman CL, Kerr WG.

J Immunol. 2006 Jun 15;176(12):7165-9.

24.

SHIP deficiency enhances HSC proliferation and survival but compromises homing and repopulation.

Desponts C, Hazen AL, Paraiso KH, Kerr WG.

Blood. 2006 Jun 1;107(11):4338-45. Epub 2006 Feb 7.

25.

Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses.

Ghansah T, Paraiso KH, Highfill S, Desponts C, May S, McIntosh JK, Wang JW, Ninos J, Brayer J, Cheng F, Sotomayor E, Kerr WG.

J Immunol. 2004 Dec 15;173(12):7324-30.

Supplemental Content

Loading ...
Support Center